Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease
03 janv. 2017 07h43 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH --(Marketwired - January 03, 2017) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School
06 déc. 2016 07h43 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - December 06, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016
15 nov. 2016 07h58 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 15, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights
10 nov. 2016 07h43 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 10, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America
05 nov. 2016 14h03 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 05, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK
03 nov. 2016 07h43 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 03, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
02 nov. 2016 08h03 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): EB-101 Phase 1 clinical trial therapy demonstrated clinical efficacy of 67% healed wounds...
Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock
01 nov. 2016 10h23 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - November 01, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
27 oct. 2016 09h12 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 27, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Announces Public Offering of Common Stock
26 oct. 2016 16h14 HE
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for...